The massive dilution overhang and toxic financing structure will likely pressure HIT shares. Watch for the November 5, 2026 stockholder vote on removing the Exchange Cap — approval would unlock full dilution. Monitor for advance notices and Yorkville resales, which will create persistent selling pressure. The company's repeated capital raises (15 filings in 24 months) suggest structural cash needs.
Price Chart
Executive Summary
Health In Tech filed an S-3 to register up to 29,532,889 shares for resale by Yorkville under a Standby Equity Purchase Agreement (SEPA) that includes up to $15M in convertible notes and a $20M equity line. The terms are highly dilutive and toxic: Yorkville buys at 97% of lowest VWAP, notes carry 8.75% interest with 5% discount and 4% payment premium, and full issuance would dilute existing holders by ~35.5%. The company has filed 15 offering/registration statements in the last 24 months, signaling persistent capital needs.
Key Financial Metrics
Key Facts
- Registers up to 29,532,889 shares for resale by Yorkville under a SEPA dated August 12, 2026
- Yorkville equity line: up to $20M in advances at 97% of lowest daily VWAP over a 3-day pricing period
- Convertible notes: up to $15M in three tranches at 8.75% interest, 5% original issue discount, fixed conversion price of $1.5735 per share with price-protection antidilution
- Exchange Cap of 13,100,378 shares (19.99% of outstanding) limits immediate issuance unless stockholder approval is obtained at the November 5, 2026 annual meeting
- If all 29.5M shares were issued, they would represent ~35.5% of total outstanding shares (83.2M) and ~58.9% of non-affiliate float
- First tranche of $6.65M (net) already disbursed on August 18, 2026; second tranche of $2.85M due upon S-3 effectiveness; third tranche of up to $4.75M at Yorkville's discretion
- Proceeds from advances must first repay convertible notes before being used for sales/distribution expansion, technology development, and working capital
- Yorkville is deemed an underwriter; no short-selling or hedging by Yorkville during SEPA term
Financial Impact
Potential dilution of up to 35.5% of outstanding shares (55% of current float) at assumed $1.00/share; maximum gross proceeds to company of $34.25M ($20M advances + $14.25M notes) but net proceeds after note repayment are uncertain
Risk Factors
- Massive dilution of up to 35.5% of outstanding shares if all shares are issued and stockholder approval is obtained
- Toxic financing structure (97% of VWAP pricing, 8.75% interest, 5% discount, 4% payment premium) creates downward price pressure
- Yorkville's ability to convert notes at a fixed price with price-protection antidilution could accelerate dilution if stock declines
- Company has filed 15 offering/registration statements in 24 months, indicating chronic capital needs and potential going-concern risk
- Failure to obtain stockholder approval at November 5 meeting could limit access to the full $20M equity line
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001213900-26-097336 |
| Document: ea030450801ex5-1.htm | 0001213900-26-097336 |
| Document: ea030450801ex-fee.htm | 0001213900-26-097336 |
| Document: ea030450801ex23-2.htm | 0001213900-26-097336 |
| Document: 0001213900-26-097336-index-headers.html | 0001213900-26-097336 |
| Document: 0001213900-26-097336-index.html | 0001213900-26-097336 |
| Document: 0001213900-26-097336.txt | 0001213900-26-097336 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+60 | — | — |
Oct 22, 2026 3d ago | 3 | $0.5623 | awaiting T+60 | — | $0.5620 (−0.05%) |
Oct 16, 2026 10d ago | 8-K | $0.6350 | awaiting T+60 | — | $0.5620 (+11.50%) |
Oct 16, 2026 10d ago | EFFECT | $0.6520 | awaiting T+60 | — | $0.5620 (+13.80%) |
Oct 13, 2026 13d ago | DEF 14A | $0.6780 | awaiting T+60 | — | $0.5620 (+17.11%) |
Oct 9, 2026 16d ago | S-3/A | $0.7200 | awaiting T+60 | — | $0.5620 (+21.94%) |
Sep 30, 2026 26d ago | Press Release | $0.7380 | awaiting T+60 | — | $0.5620 (−23.85%) |
Sep 29, 2026 27d ago | SC 13G | $0.8525 | awaiting T+60 | — | $0.5620 (−34.08%) |
Sep 4, 2026 7w ago | S-3 | $0.9801 | awaiting T+60 | — | $0.5620 (+42.66%) |
Aug 13, 2026 10w ago | Press Release | $1.01 | awaiting T+60 | — | $0.5620 (+44.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers